Adtalem Global Education (NYSE:CVSA) CFO Sells $326,831.46 in Stock

Adtalem Global Education Inc. (NYSE:CVSA) CFO Robert Phelan sold 2,414 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $135.39, for a total transaction of $326,831.46. Following the completion of the sale, the chief financial officer directly owned 50,492 shares of the company’s stock, valued at approximately $6,836,111.88. This represents a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adtalem Global Education Stock Up 0.2%

Shares of CVSA traded up $0.32 during trading hours on Thursday, reaching $131.17. 316,206 shares of the company traded hands, compared to its average volume of 371,981. Adtalem Global Education Inc. has a 12 month low of $86.97 and a 12 month high of $156.26. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.70 and a quick ratio of 0.70. The firm has a fifty day moving average price of $124.04. The stock has a market cap of $4.46 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 1.02 and a beta of 0.62.

Adtalem Global Education (NYSE:CVSA) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.73 by $0.25. Adtalem Global Education had a net margin of 12.26% and a return on equity of 20.19%. The company had revenue of $487.03 million during the quarter. During the same period in the previous year, the company earned $1.92 earnings per share. Adtalem Global Education’s quarterly revenue was up 4.5% on a year-over-year basis. Adtalem Global Education has set its FY 2026 guidance at 7.950-8.150 EPS. On average, analysts expect that Adtalem Global Education Inc. will post 8.04 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on CVSA. Weiss Ratings restated a “hold (c+)” rating on shares of Adtalem Global Education in a research note on Friday, May 22nd. Zacks Research cut Adtalem Global Education from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 25th. Barrington Research reiterated an “outperform” rating and issued a $170.00 price objective on shares of Adtalem Global Education in a report on Monday, June 8th. Truist Financial raised their price objective on Adtalem Global Education from $130.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, Wall Street Zen upgraded shares of Adtalem Global Education from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $155.00.

About Adtalem Global Education

Adtalem Global Education (NYSE: CVSA) is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.

Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.